VANCOUVER, BC, May 13, 2024
/PRNewswire/ -- WAT Medical, a leader in innovative healthcare
solutions, announces the development of ObeEnd, the world's first
weight management wristband backed by clinical evidence showcasing
its efficacy in reducing dietary intake. Findings from this
groundbreaking study were presented at the Canadian Nutrition
Society annual conference in May
2024.
According to the World Health Organization (WHO), the global
prevalence of obesity has reached alarming proportions, affecting
one in eight individuals worldwide. With 2.5 billion adults
classified as overweight in 2022, a figure that has more than
doubled since 1990, addressing this epidemic has become a paramount
global health concern. The Centers for Disease Control and
Prevention (CDC) has identified obesity as a prevalent, serious,
and costly disease, linked to numerous debilitating conditions
including heart disease, stroke, diabetes, and cancer, all of which
contribute to premature mortality rates.
While medical interventions for weight loss exist, such as
surgical procedures or pharmaceuticals like the FDA-approved Wegovy
(semaglutide injection), these options often present significant
drawbacks including adverse side effects, inconsistent outcomes,
and challenges in sustaining weight loss post-treatment cessation.
Studies have shown that discontinuing semaglutide injections can
lead to rapid weight regain, underscoring the need for
alternative solutions.
WAT Medical's mission is to offer a safe and effective
alternative for weight management, and ObeEnd represents a paradigm
shift in this pursuit. Leveraging neuromodulation technology,
ObeEnd delivers targeted electrical impulses via PC6 to mitigate
gastric secretion while enhancing post-exercise recovery. Clinical
studies have demonstrated that ObeEnd results in significant
reduction in caloric intake and pepsinogen-1 production. The
mechanism underlying ObeEnd's efficacy is believed to be
sympathetic inhibition, which have also demonstrated efficacy in
alleviating symptoms of nausea, vomiting, and even reducing blood
pressure levels.
The encouraging clinical results of ObeEnd mark a significant
milestone towards the realization of an innovative, drug-free
wearable solution for weight management. Ongoing clinical studies,
conducted in collaboration with Concordia
University, aim to further substantiate these findings, with
additional data anticipated in the near future.
For further information on ObeEnd and WAT Medical's pioneering
efforts in healthcare innovation, please visit watmedical.com.
References
[1] Rachel Abramczuk,
Sarah Feola, Lyne Al-Nabelsi, and
Sylvia Santosa. The effect of PC6
stimulation on dietary intake and appetite[J]. Applied Physiology,
Nutrition, and Metabolism, 2024, 49: 20-21.
[2] https://www.who.int/news-room/fact-sheets/detail/obesity-and
overweight#:~:text=Key%20facts,years%20and%20older)%20were%20overweight.
[3] https://www.cdc.gov/obesity/data/adult.html
[4]
https://health.ucdavis.edu/blog/cultivating-health/ozempic-for-weight-loss-does-it-work-and-what-do-experts-recommend/2023/07#:~:text=However%2C%20semaglutide%20is%20approved%20for,it%2C%20establishing%20a%20new%20normal.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/obeend---pioneering-drug-free-weight-management-wristband-302143248.html
SOURCE WAT Medical Enterprise Ltd.